ABSTRACT Objective: To compare the efficacy and the period of use of tocilizumab and infliximab during treatment of rheumatoid arthritis patients. Methods: The period of use of two biologics with different mechanisms of action were compared in treatment of rheumatoid arthritis patients. Results: Both medications showed efficacy, but the period of use with no loss of efficacy was longer in patients receiving tocilizumab when compared to infliximab. Conclusion: Tocilizumab maintains a period of use significantly longer as compared with infliximab in patients with rheumatoid arthritis treated at a single organization.
All Keywords
【저자키워드】 antibodies, Arthritis, Biological agents, monoclonal/therapeutic use, rheumatoid/drug therapy,
【저자키워드】 antibodies, Arthritis, Biological agents, monoclonal/therapeutic use, rheumatoid/drug therapy,